ArticleResearch square2026
A Human Lymph node-on-a-Chip for Personalized Evaluation of Vaccine Immunogenicity.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Vaccines have revolutionized public health, yet their development remains hampered by the poor predictive power of animal models, leading to high clinical failure rates and variable efficacy across populations. To bridge this translational gap, we developed a human lymph node-on-a-chip model that biomimetically reproduces key physiological features of human lymph node, including compartmentalized immune cell zones and functional stromal networks. This immunocompetent model recapitulates the complete cascade of vaccine-induced adaptive immune processes in human lymph nodes, from antigen presentation, immune cell differentiation to germinal center formation and antibody secretion, providing a human-relevant platform for preclinical vaccine testing. Using donor-matched immune cells from influenza vaccine trials, we established a personalized clinical-trial-on-chip platform that accurately mirrors individual vaccine responses. Benchmarking on-chip immunogenicity readouts against clinical serological and transcriptomic data confirmed the platform's predictive power for assessing vaccine efficacy across diverse populations. Our study uncovered a key mechanism of vaccine failure in vulnerable populations: age- and comorbidities-related factors impair T follicular helper cell differentiation and disrupt critical T-B cell interactions. Single-cell transcriptomic profiling revealed critical immune signaling networks involving MyD88 in DCs, IL-2/STAT5 balance in T cells, and TACI/BCMA activation in B cells that collectively govern the efficiency of the adaptive immune cascade. These mechanistic insights enabled us to validate clinically actionable strategies, including dose escalation and IL-2 cytokine adjuvant as effective countermeasures to enhance immunogenicity efficiency in immunocompromised individuals. These results demonstrate the potential of this human lymph node-on-a-chip as a transformative precision vaccinology tool for personalized vaccine immunogenicity assessment and optimization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.